WHO ICTRP trial
Thiotepa, fludarabine plus busulfan regimen as conditioning regimen prior to…
ChiCTR2400088533 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2400088533 |
|---|---|
| Public title | Thiotepa, fludarabine plus busulfan regimen as conditioning regimen prior to allo-HSCT for adult acute lymphoblastic leukemia:a prospective,single-arm, phase 2 study |
| Scientific title | Thiotepa, fludarabine plus busulfan regimen as conditioning regimen prior to allo-HSCT for adult acute lymphoblastic leukemia:a prospective,single-arm, phase 2 study |
| Primary sponsor | The First Affiliated Hospital, College of Medicine, Zhejiang University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 2 |
| Countries | China |
| Conditions | Acute lymphoblastic leukemia |
| Interventions | Group A:thiotepa, fludarabine plus busulfan regimen as conditioning regimen prior to allo-HSCT |
| Registration date | Aug 20, 2024 |
| Target size | Group A:80 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: